BBI Solutions launches new synthetic Rubella IgM serum to the diagnostics market

SITTINGBOURNE, U.K. - April 28, 2014 - PRLog -- Used in the manufacture of control solutions for Rubella testing and ToRCH screening for perinatal diseases, synthetic Rubella IgM disease state serum is formulated in delipidated, defibrinated plasma that has been designed to mimic a high titre native Rubella IgM disease state serum. In its native form, Rubella IgM is one of the most difficult disease state serum/plasma to source at high titre making securing supply chain a challenge for IVD companies.

The product has been designed to be of a high and consistent titre and it has been tested across multiple test platforms. Results have demonstrated successful performance across the top analytical test platforms including; Abbott ARCHITECT, Siemens IMMULITE® 1000, Roche cobas® and bioMérieux VIDAS®. It is also negative for Rubella IgG, eliminating the risk of false positives.

Traditionally, control solutions are created from the serum of someone suffering with a disease, in this case, someone with Rubella. However, since most people are vaccinated for Rubella at a young age it is often difficult to source a sufferer of Rubella. Therefore, to make the controls, a synthetic disease state serum product that has shown excellent linearity upon dilution is a great alternative.

BBI can offer high reproducibility, excellent batch to batch consistency and the same concentration and similar recovery with every batch, which would not be possible with native material. This makes it ideal for use as a raw material when developing controls and calibrators to support assay development and test manufacturing.

BBI can offer customers a secure, long term supply of the product, a product that is somewhat difficult to source in the diagnostics market. BBI are making small amounts of material available for testing, visit www.bbisolutions.com/synthetic-rubella-igm-serum to find out more or request an evaluation sample.